MARLBOROUGH, October 17, 2025 – Boston Scientific (BSX) said it will acquire remaining equity in Nalu Medical for 533 million, expanding its chronic pain therapy portfolio through neurostimulation technology 1. The deal gives the medical device maker access to targeted pain relief systems for adults with chronic conditions.
- Boston Scientific buying rest of Nalu Medical for 533 million
- Deal expands chronic pain neurostimulation device portfolio significantly
- Transaction expected to close in first half of 2026
Market Reaction & Context
Boston Scientific shares gained in Friday trading following the acquisition announcement 8. The deal represents Boston Scientific’s continued expansion in the pain management sector, where medical device companies are increasingly focusing on neurostimulation technologies as alternatives to opioid treatments.
The company initially invested in Nalu in 2017, making this acquisition a strategic follow-up to deepen its involvement in the chronic pain market 5. Medical device peers have similarly pursued pain management acquisitions as the sector grows amid rising demand for non-pharmacological treatments.
Deal Structure & Timeline
Boston Scientific will pay the 533 million upfront in cash for the remaining equity it does not already own in the privately-held California-based company 9. The transaction is subject to customary closing conditions and regulatory approvals.
The acquisition is expected to complete in the first half of 2026, with Nalu anticipated to generate more than 60 million in revenue 6. Excluding one-time items, Boston Scientific said the transaction is expected to be immaterial to earnings initially.
Technology & Market Opportunity
The deal provides Boston Scientific access to Nalu’s neurostimulation device designed to deliver targeted relief to adults living with chronic pain conditions 7. This technology represents a growing segment within pain management as healthcare providers seek alternatives to traditional pharmaceutical approaches.
Neurostimulation devices work by sending electrical pulses to specific nerve pathways, potentially providing pain relief without the side effects associated with long-term medication use. The chronic pain market has attracted significant medical device investment as companies develop more sophisticated, targeted treatment options.
Strategic Rationale
The acquisition aligns with Boston Scientific’s broader strategy to expand its portfolio of minimally invasive medical technologies. The company has been actively acquiring smaller firms with specialized technologies that complement its existing product lines.
By bringing Nalu’s neurostimulation technology in-house, Boston Scientific can leverage its global distribution network and regulatory expertise to accelerate market penetration. The deal also positions the company to compete more effectively in the growing chronic pain management sector.
Outlook
Boston Scientific expects the Nalu acquisition to contribute to its pain management portfolio growth, though specific financial guidance beyond the revenue projection was not disclosed. The company continues to evaluate additional acquisition opportunities in adjacent therapeutic areas.
The transaction reflects broader industry consolidation in medical technology, where larger companies are acquiring innovative startups to enhance their competitive positioning in specialized markets like chronic pain management.
Not investment advice. For informational purposes only.
References
1“Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.” (October 17, 2025). Boston Scientific News. Retrieved October 17, 2025.
2“Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.” (October 17, 2025). PR Newswire. Retrieved October 17, 2025.
3“Boston Scientific boosts chronic pain therapy portfolio with Nalu deal” (October 17, 2025). Reuters. Retrieved October 17, 2025.
4“Boston Scientific to purchase California medtech for 533M” (October 17, 2025). Worcester Business Journal. Retrieved October 17, 2025.
5“Boston Scientific to Buy Rest of Nalu Medical for 533 Million” (October 17, 2025). Morningstar. Retrieved October 17, 2025.
6“Boston Scientific to acquire Nalu Medical for 533M” (October 17, 2025). MassDevice. Retrieved October 17, 2025.
7“Boston Scientific boosts chronic pain therapy portfolio with Nalu deal” (October 17, 2025). Yahoo Finance. Retrieved October 17, 2025.
8“Why Is Boston Scientific Stock Gaining Friday?” (October 17, 2025). Benzinga. Retrieved October 17, 2025.
9“Boston Scientific To Buy Nalu Medical For Upfront 533 Mln Cash” (October 17, 2025). Nasdaq. Retrieved October 17, 2025.